Safety, Tolerability and PK Study of AK0529 in Healthy Human

NCT02297594 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG: AK0529
DRUG: Placebo

Sponsor

Shanghai Ark Biopharmaceutical Co., Ltd.